Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (15810)	2/24/1998 9:27:00 PM
From: Torben Noerup Nielsen	Read Replies (2) \| Respond to of 32384

By the way, note that in licensing the Glycomed technology, Ligand is once again showing that they are conducting business according to their business plan: aggressively pursue certain markets themselves while licensing incidental compounds/technologies as appropriate. Sounds good to me. I like to see a management team following their stated business plan. It increases my connfidence in the operation as a whole. Note that this is just one more potential revenue source. And Ligand really didn't have the time/resources to pursue it. Kudos to Robinson for not letting himself be distracted by it. By the way, how often do young and biotechs licence to other biotechs like this? Seems to me this is a sign of maturity. If someone feels otherwise, let me know. Anything to get a heated discussion going over something other than a fraction of a point in price..... :-) Cheers, Torben